RCC Treatment Strategies in a Poor-Risk Patient - a podcast by ReachMD

CME credits: 0.50

Valid until: 27-08-2022

Claim your CME credit at https://reachmd.com/programs/cme/rcc-treatment-strategies-in-a-poor-risk-patient/12797/

Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.

After viewing the activity, visit the Related tab for supplemental resources.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD